Mercado de diagnóstico de cáncer gástrico en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2030

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de diagnóstico de cáncer gástrico en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2030

  • Healthcare IT
  • Published Report
  • Mar 2023
  • MEA
  • 350 Páginas
  • Número de tablas: 160
  • Número de figuras: 56

Middle East And Africa Gastric Cancer Diagnostics Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2024 –2030
Diagram Tamaño del mercado (año base)
MILLONES DE DÓLARES
Diagram Tamaño del mercado (año de pronóstico)
USD 69.63
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado de diagnóstico de cáncer gástrico en Oriente Medio y África, por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas): tendencias de la industria y pronóstico hasta 2030.

Mercado de diagnóstico de cáncer gástrico en Oriente Medio y África

Análisis y perspectivas del mercado de diagnóstico de cáncer gástrico en Oriente Medio y África

El aumento de la población geriátrica en Oriente Medio y África está impulsando el crecimiento de la industria de diagnóstico del cáncer gástrico. La prevalencia de tumores gastrointestinales y linfomas también ha impulsado la demanda de diagnósticos de cáncer gástrico. La principal limitación del mercado es la necesidad de reducir los altos precios asociados con las pruebas de diagnóstico del cáncer para que incluso los países en desarrollo puedan beneficiarse de ellas.

Mercado de diagnóstico de cáncer gástrico en Oriente Medio y ÁfricaMercado de diagnóstico de cáncer gástrico en Oriente Medio y África

Un gran número de actores del mercado están ofreciendo productos de diagnóstico de cáncer gástrico con innovaciones que allanan el camino para el crecimiento del mercado de diagnóstico de cáncer gástrico en Medio Oriente y África.

Data Bridge Market Research analiza que se espera que el mercado de diagnóstico de cáncer gástrico en Oriente Medio y África alcance un valor de 69,63 millones de dólares en 2030, con una tasa de crecimiento anual compuesta del 7,4 % durante el período de pronóstico. Los reactivos y consumibles representan el segmento de tipo de producto más grande del mercado debido a la creciente demanda de kits y reactivos, y el aumento del gasto en salud ha acelerado la demanda de dispositivos médicos inteligentes.

Métrica del informe

Detalles

Período de pronóstico

2023 a 2030

Año base

2022

Años históricos

2021 (Personalizable para 2015-2020)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas)

Países cubiertos

Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto y el resto de Oriente Medio y África.

Actores del mercado cubiertos

BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Middle East and Africa Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Middle East and Africa gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Middle East and Africa gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • En octubre de 2022, General Electric Company colaboró ​​con varios institutos de investigación como los Hospitales de la Universidad de Cambridge, Sophia Genetics y anteriormente con Optellum para utilizar datos de imágenes en colaboración con inteligencia artificial. Esto ayudará a reducir el tiempo de diagnóstico de varios tipos de cáncer y ayudará a brindar atención personalizada a los pacientes. Esto ha ayudado a la empresa a ampliar sus horizontes en el diagnóstico del cáncer.
  • En marzo de 2020, Thermo Fisher Scientific Inc. anunció que adquiriría QIAGEN, una empresa holandesa de diagnóstico molecular y atención médica. Esta adquisición por parte de la empresa aumentará su cartera de productos en el mercado, lo que generará un aumento de los ingresos en el futuro.

Alcance del mercado de diagnóstico de cáncer gástrico en Oriente Medio y África

El mercado de diagnóstico de cáncer gástrico de Oriente Medio y África está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo de edad, el tipo de enfermedad, la etapa, el género, la muestra, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

TIPO DE PRODUCTO

  • Instrumentos
  • Reactivos y consumibles
  • Servicios

Según el tipo de producto, el mercado se segmenta en instrumentos, reactivos y consumibles y servicios.

TIPO DE DIAGNÓSTICO

  • Prueba confirmatoria
  • Pruebas de detección de cáncer gástrico/examen físico

Según el tipo de diagnóstico, el mercado está segmentado en pruebas de detección de cáncer gástrico/examen físico y pruebas confirmatorias.

GRUPO DE EDAD

  • Adulto
  • Pediátrico
  • Geriatría

Según el grupo de edad, el mercado se segmenta en adultos, pediátricos y geriátricos.

TIPO

  • Adenocarcinoma intestinal o difuso
  • Tumor carcinoide
  • Tumor del estroma gastrointestinal (GIST)
  • Linfoma gástrico
  • Otros

Según el tipo, el mercado está segmentado en adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros.

ESCENARIO

  • Etapa 0
  • Etapa I
  • Estadio II
  • Estadio III

En función de la etapa, el mercado se segmenta en etapa 0, etapa I, etapa II y etapa III.

GÉNERO

  • Masculino
  • Femenino

En función del género, el mercado está segmentado en masculino y femenino.

TIPO DE MUESTRA

  • Sangre
  • Tejido
  • Orina
  • Heces

Según el tipo de muestra, el mercado se segmenta en sangre, tejido, orina y heces.

USUARIO FINAL

  • Laboratorios de diagnóstico
  • Hospitales
  • Institutos de investigación del cáncer
  • Clínicas especializadas en oncología
  • Otros

Sobre la base de los usuarios finales, el mercado está segmentado en laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros.

CANAL DE DISTRIBUCIÓN

  • Licitaciones directas
  • Ventas al por menor

Sobre la base del canal de distribución, el mercado está segmentado en licitación directa y ventas minoristas.

Análisis y perspectivas regionales del mercado de diagnóstico de cáncer gástrico en Oriente Medio y África

El mercado de diagnóstico de cáncer gástrico de Medio Oriente y África está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo de edad, el tipo de enfermedad, la etapa, el género, la muestra, el usuario final y el canal de distribución. 

Los países cubiertos en este informe de mercado son Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel y el resto de Medio Oriente y África.

Se espera que en 2023, Sudáfrica domine debido a la creciente necesidad de una comunicación sanitaria eficiente y receptiva.

La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Medio Oriente y África y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de los diagnósticos de cáncer gástrico

El panorama competitivo del mercado de diagnóstico de cáncer gástrico en Oriente Medio y África proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y la extensión del producto, el dominio de la aplicación, la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado de diagnóstico de cáncer gástrico.

Algunos de los principales actores que operan en el mercado de diagnóstico de cáncer gástrico en Medio Oriente y África son BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc. y QIAGEN, entre otros.

 


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA

6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

6.1.3 INCREASE IN THE GERIATRIC POPULATION

6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST

6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES

6.3 OPPORTUNITIES

6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS

6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES

6.4.2 LIMITATIONS OF RADIATION TESTS

7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.2.1 KITS

7.2.1.1 DNA POLYMERASE KITS

7.2.1.2 PCR KITS

7.2.1.3 NUCLEIC ACID ISOLATION KITS

7.2.1.4 OTHERS

7.2.2 REAGENTS

7.2.2.1 ASSAYS

7.2.2.2 BUFFERS

7.2.2.3 PRIMERS

7.2.2.4 OTHERS

7.3 INSTRUMENTS

7.4 SERVICES

8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

8.1 OVERVIEW

8.2 CONFIRMATORY TEST

8.2.1 IMAGING TESTS

8.2.1.1 PET SCAN/CT SCAN

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 MRI

8.2.1.5 X-RAY

8.2.2 BIOMARKER

8.2.2.1 DNA BIOMARKER

8.2.2.2 RNA BIOMARKER

8.2.2.3 PROTEIN BIOMARKER

8.2.3 BIOPSY

8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM

9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

9.1 OVERVIEW

9.2 GERIATRICS

9.3 ADULT

9.4 PEDIATRIC

10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA

10.3 CARCINOID TUMOR

10.4 GASTROINTESTINAL STROMAL TUMOR

10.5 GASTRIC LYMPHOMA

10.6 OTHERS

11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE

11.1 OVERVIEW

11.2 STAGE I

11.2.1 STAGE IA

11.2.2 STAGE IB

11.3 STAGE II

11.3.1 STAGE IIA

11.3.2 STAGE IIB

11.4 STAGE III

11.4.1 STAGE IIIA

11.4.2 STAGE IIIB

11.4.3 STAGE IIIC

11.5 STAGE 0

12 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

13.1 OVERVIEW

13.2 STOOL

13.3 TISSUE

13.4 BLOOD

13.5 URINE

14 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC LABORATORIES

14.4 CANCER RESEARCH INSTITUTES

14.5 ONCOLOGY SPECIALTY CLINICS

14.6 OTHERS

15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION

16.1 MIDDLE EAST AND AFRICA

16.1.1 SOUTH AFRICA

16.1.2 SAUDI ARABIA

16.1.3 U.A.E

16.1.4 EGYPT

16.1.5 ISRAEL

16.1.6 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GENERAL ELECTRIC

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 QIAGEN

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 MYRIAD GENETICS, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACON LABORATORIES, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ADVACARE PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AGILENT TECHNOLOGIES, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 BIOMÉRIEUX

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BIOCEPT, INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 BIOHIT OYJ

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DIASORIN S.P.A

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 ENDOFOTONICS PTE LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 FOUNDATION MEDICINE, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 FUJIREBIO (AN H.U. GROUP COMPANY)

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 MIRXES PTE LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 PARAGON GENOMICS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TECO DIAGNOSTICS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 VELA DIAGNOSTICS

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tablas

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 70 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 SOUTH AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 SOUTH AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 SOUTH AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 SOUTH AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 78 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 79 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 80 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 SOUTH AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 SOUTH AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 84 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 85 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 86 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 SAUDI ARABIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SAUDI ARABIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 SAUDI ARABIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 SAUDI ARABIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 SAUDI ARABIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 SAUDI ARABIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 96 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 97 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 98 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 SAUDI ARABIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 SAUDI ARABIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 SAUDI ARABIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 102 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 103 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 104 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 105 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 106 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 U.A.E REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 U.A.E KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 U.A.E REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 110 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 U.A.E CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 U.A.E IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 U.A.E BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 114 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 115 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 116 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 U.A.E STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 U.A.E STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 U.A.E STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 120 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 121 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 122 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 123 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 124 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 EGYPT REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 EGYPT KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 EGYPT REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 129 EGYPT CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 130 EGYPT IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 131 EGYPT BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 132 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 133 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 134 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 135 EGYPT STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 136 EGYPT STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 137 EGYPT STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 138 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 139 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 140 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 141 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 142 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 ISRAEL REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 ISRAEL KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 ISRAEL REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 147 ISRAEL CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 148 ISRAEL IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 149 ISRAEL BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 150 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 151 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 152 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 153 ISRAEL STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 154 ISRAEL STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 155 ISRAEL STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 156 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 157 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 160 REST OF MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Lista de figuras

FIGURE 1 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID

FIGURE 11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

FIGURE 15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 18 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022

FIGURE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)

FIGURE 22 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 24 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022

FIGURE 28 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)

FIGURE 30 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022

FIGURE 32 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 36 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022

FIGURE 40 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 44 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Middle East and Africa Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 7.4% during the forecast period by 2030.
The future market value of the Middle East and Africa Gastric Cancer Diagnostics Market is expected to reach USD 69.63 million by 2030.
The major players in the Middle East and Africa Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Middle East and Africa Gastric Cancer Diagnostics Market are Saudi Arabia, South Africa, U.A.E, Israel, Egypt, and rest of Middle East and Africa.